---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-008433"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T21:41:46.365087+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fortress closes sale of Checkpoint to Sun Pharma; receives ~$28M cash plus milestones

## Summary
- Checkpoint merged into Sun Pharma on May 30, 2025; deconsolidated from Fortress.
- Fortress gets ~$28.0M cash at close, up to $4.8M regulatory milestone, and quarterly royalty of 2.5% on certain product net sales.
- Pro forma gain on deconsolidation is $26.6M; pro forma net loss attributable to common stockholders improves from $(0.48) to $0.57 per share for Q1 2025.

## SEC filing metadata
- accession: 0001558370-25-008433
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837025008433/0001558370-25-008433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837025008433/fbio-20250530x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-008433
- JSON: https://secwatch.observer/filing/0001558370-25-008433.json
- Plain text: https://secwatch.observer/filing/0001558370-25-008433.txt

## Key facts
- M&A Transactions
  Fortress Biotech, Inc. completed a disposition involving Sun Pharmaceutical Industries, Inc. for approximately $28.0 million in cash (closed 2025-05-30).
  - Action: disposition
  - Counterparty: Sun Pharmaceutical Industries, Inc.
  - Consideration: approximately $28.0 million in cash
  - Closing: 2025-05-30
  source text: as a subsidiary of Fortress (the “Subsidiary Sale”). In connection with the closing of the Merger and pursuant to the Merger Agreement, Fortress will receive approximately $28.0 million in cash and be eligible to receive up to an additional $4.8 million upon achievement of a regulatory milestone associated with the rights (“CVRs”) issued under a Contingent Value
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000155837025008433/0001558370-25-008433-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.